表紙
市場調查報告書

抗生素製造前25家:頭孢菌素、青霉素、Fluoroquinolones 、大環內酯類、碳青霉烯類、其他

Top 25 Antibiotic Drugs Manufacturers 2018: US, Europe, Japan, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Others

出版商 Visiongain Ltd 商品編碼 678918
出版日期 內容資訊 英文 250 Pages
商品交期: 最快1-2個工作天內
價格
抗生素製造前25家:頭孢菌素、青霉素、Fluoroquinolones 、大環內酯類、碳青霉烯類、其他 Top 25 Antibiotic Drugs Manufacturers 2018: US, Europe, Japan, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Others
出版日期: 2018年06月12日內容資訊: 英文 250 Pages
簡介

2022年的全球抗生素的市場估計為438億4170萬美元,預計從2022年到2028年以3.4%的年複合成長率 (CAGR) 成長。

本報告提供全球抗生素製造的市場調查,市場概要,市場成長的各種影響因素及市場機會分析,世界市場趨勢,各藥物類型的銷售情況與預測,前25家抗生素製造公司的簡介,各產品系列、產品的銷售額預測,SWOT分析,市場未來展望等資料彙整。

第1章 報告概要

第2章 簡介:抗生素製造商

  • 市場概要
    • 頭孢菌素
    • 青霉素
    • 奎諾酮類抗生素(Quinolones)/Fluoroquinolones
    • 大環內酯類
    • 碳青霉烯類
  • 成長推動因素、阻礙成長要素、市場機會

第3章 全球市場的變化與預測

  • 市場變化與預測
  • 銷售情況與預測:各類型
  • 主要的抗生素製造商
  • 抗生素市場上主要企業
  • 銷售情況與預測:各類型
    • 頭孢菌素
    • 青霉素
    • Fluoroquinolones
    • 大環內酯類
    • 碳青霉烯類
    • 其他

第4章 美國:主要製造商分析、預測

  • Pfizer, Inc.
  • Merck & Co.
  • Johnson & Johnson
  • Cubist Pharmaceuticals
  • Abbott Laboratories
  • Eli Lilly & Co.
  • Melinta Therapeutics, Inc.
    • 產品系列
    • 銷售額預測:各產品
    • SWOT分析

第5章 歐洲:主要製造商分析、預測

  • Novartis
  • GlaxoSmithKline plc
  • Bayer AG
  • Allergan plc
  • F. Hoffmann-La Roche AG
  • Sanofi
  • STADA Arzneimittel
    • 產品系列
    • 銷售額預測:各產品
    • SWOT分析

第6章 日本:主要製造商分析、預測

  • 鹽野義製藥
  • 大正製藥
  • 第一三共
  • 明治集團
  • Astellas Pharma Inc.
    • 產品系列
    • 銷售額預測:各產品
    • SWOT分析

第7章 其他地區:主要製造商分析、預測

  • Sun Pharmaceutical Industries
  • Cipla
  • Lupin Limited
  • Shanghai Pharmaceuticals Holding
  • Dr. Reddy's Laboratories
  • TaiGen Biotechnology
    • 產品系列
    • 銷售額預測:各產品
    • SWOT分析

第8章 總論

附錄

目錄
Product Code: PHA0316

Visiongain forecasts the antibiotic drugs market to increase to $ 43,841.7m in 2022. The market is estimated to grow at a CAGR of 3.4% between 2022 and 2028. In 2017, Pfizer held the largest market share of the antibiotic drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 181 tables and 111 figures - all unavailable elsewhere.

The 250-page report provides clear detailed insight into the top 25 antibiotic drugs manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Antibiotic Drugs Market Forecast from 2018-2028, further segmented by type:

  • Cephalosporins
  • Penicillins
  • Fluoroquinolones
  • Macrolides
  • Carbapenems
  • Others

This report provides analysis of the leading antibiotic drugs manufacturers in the US, including forecasts from 2018-2028 of the company's antibiotic drugs revenues, where possible:

  • Pfizer: Sulperazon, Unasyn, Zithromax, Dalacin, Merrem/Meropen, Zyvox, Tygacil, Others
  • Merck & Co.: Cubicin, Invanz, Avelox, Primaxin, Others
  • Johnson & Johnson: Zeftera, Sirturo, Others
  • Cubist Pharmaceuticals: Cubicin, Sivextro Oral
  • Abbott Laboratories: Baxin, Others
  • Eli Lilly & Co.: Vancocin, Ceclor
  • Melinta Therapeutics, Inc: Orbactiv, Others

This report provides analysis of the leading antibiotic drugs manufacturers in Europe, including forecasts from 2018-2028 of the company's antibiotic drugs revenues, where possible:

  • Novartis: Vigamox, Ciprodex, TOBI Podhaler, Cubicin
  • GlaxoSmithKline: Ceftin/Zinnat, Augmentin IR, Amoxil, Others
  • Bayer: Avelox, Cipro/Cirpobay
  • Allergan: Zinforo/Teflaro, Dalbavancin, Others
  • Roche: Rocephin
  • Sanofi: Targocid, Others
  • STADA Arzneimittel: Amoxicillin, Diclofenac Sodium

This report provides analysis of the leading antibiotic drugs manufacturers in Japan, including forecasts from 2018-2028 of the company's antibiotic drugs revenues, where possible:

  • Shionogi & Co., Ltd.: Flomox/Flumarin, Others
  • Taisho Pharmaceutical Holdings: Geninax, Biaxin/Clarith, Zosyn/Tazocin
  • Daiichi Sankyo: Cravit, Levaquin, Others
  • Meiji Holdings Company, Ltd.: Meiact/Spectracef, Others
  • Astellas Pharma: Dificid, Others

This report provides analysis of the leading antibiotic drugs manufacturers in other countries, including forecasts from 2018-2028 of the company's antibiotic drugs revenue, where possible:

  • Sun Pharmaceutical Industries: Ciprofloxacin Hydrochloride, Others
  • Cipla: Amoxicillin, Others
  • Lupin: Cefixime, Cephalexin, Others
  • Shanghai Pharmaceuticals Holding: Cefotaxime Sodium, Cefotiam Hydrochloride, Ceftriaxone Sodium
  • Dr. Reddy's Laboratories: Cefotaxime Sodium, Cefotiam Hydrochloride, Ceftriaxone Sodium
  • TaiGen Biotechnology: Taigexyn

Visiongain's study is intended for anyone requiring commercial analyses for the top 25 antibiotic drugs manufacturers. You find data, trends and predictions.

Buy our report today Top 25 Antibiotic Drugs Manufacturers 2018: US, Europe, Japan, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Others.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Antibiotics Drugs Manufacturer Market Overview
  • 1.2. Overview of Findings
  • 1.3. Structure of the Report
  • 1.4. Global Antibiotics Drugs Manufacturer Market Segmentation
  • 1.5. Why You Should Read This Report
  • 1.6. Key Questions Answered by This Analytical Report
  • 1.7. Who is This Report For?
  • 1.8. Methodology
  • 1.9. Associated Visiongain Report
  • 1.10. About Visiongain

2. Introduction to Antibiotics Drugs Manufacturer

  • 2.1. An Introduction to Antibiotics Drugs Manufacturer
    • 2.1.1. Cephalosporins
    • 2.1.2. Penicillins
    • 2.1.3. Quinolones/Fluoroquinolones
    • 2.1.4. Macrolides
    • 2.1.5. Carbapenems
  • 2.2. Antibiotics Drugs Manufacturer Market: Drivers, Restrains and Opportunities
    • 2.2.1. Drivers
      • 2.2.1.1. Need of new broad-spectrum agents
      • 2.2.1.2. Increase in Government Funding
      • 2.2.1.3. Infection control in health care settings
      • 2.2.1.4. Rapidly growing antibacterial resistance
    • 2.2.2. Restrains
      • 2.2.2.1. Inappropriate prescription and patient compliance
      • 2.2.2.2. Lack of return on investment
    • 2.2.3. Opportunities
      • 2.2.3.1. Public-Private Funding

3. Antibiotics Drugs: World Market 2018-2028

  • 3.1. Global Antibiotics Drugs Market Forecast, 2018-2028
  • 3.2. Global Antibiotics Drugs Market, by Automation Type: Sales Forecast 2018-2028
  • 3.3. Leading Antibiotics Drugs Manufacturer
  • 3.4. Leading Companies in the Antibiotics Drugs Market
  • 3.5. Antibiotics Drugs Market Segments: Sales Forecasts 2018-2028
    • 3.5.1. Cephalosporins Drugs Market: Sales Forecast 2018-2028
    • 3.5.2. Penicillins Drugs Market: Sales Forecast 2018-2028
    • 3.5.3. Fluoroquinolones Drugs Market: Sales Forecast 2018-2028
    • 3.5.4. Macrolides Drugs Market: Sales Forecast 2018-2028
    • 3.5.5. Carbapenems Drugs Market: Sales Forecast 2018-2028
    • 3.5.6. Others Drugs Market: Sales Forecast 2018-2028

4. Leading US Antibiotics Drugs Manufacturers 2018-2028

  • 4.1. Pfizer, Inc.: Overview
    • 4.1.1. Pfizer: Antibiotics Drugs Portfolio
    • 4.1.2. Pfizer Antibiotics Drug Sales Forecast 2018-2028
      • 4.1.2.1. Sulperazon
      • 4.1.2.2. Sulperazon: Sales Forecast 2018-2028
      • 4.1.2.3. Unasyn
      • 4.1.2.4. Unasyn: Sales Forecast 2018-2028
      • 4.1.2.5. Zithromax
      • 4.1.2.6. Zithromax: Sales Forecast 2018-2028
      • 4.1.2.7. Dalacin
      • 4.1.2.8. Dalacin: Sales Forecast 2018-2028
      • 4.1.2.9. Merrem/Meropen
      • 4.1.2.10. Merrem/Meropen: Sales Forecast 2018-2028
      • 4.1.2.11. Zyvox
      • 4.1.2.12. Zyvox: Sales Forecast 2018-2028
      • 4.1.2.13. Tygacil
      • 4.1.2.14. Tygacil: Sales Forecast 2018-2028
      • 4.1.2.15. Others
      • 4.1.2.16. Others: Sales Forecast 2018-2028
    • 4.1.3. Pfizer: SWOT Analysis
  • 4.2. Merck & Co.: Overview
    • 4.2.1. Merck & Co.: Antibiotics Drugs Portfolio
    • 4.2.2. Merck & Co. Antibiotics Drug Sales Forecast 2018-2028
      • 4.2.2.1. Cubicin
      • 4.2.2.2. Cubicin: Sales Forecast 2018-2028
      • 4.2.2.3. Invanz
      • 4.2.2.4. Invanz: Sales Forecast 2018-2028
      • 4.2.2.5. Avelox
      • 4.2.2.6. Avelox: Sales Forecast 2018-2028
      • 4.2.2.7. Primaxin
      • 4.2.2.8. Primaxin: Sales Forecast 2018-2028
      • 4.2.2.9. Others
      • 4.2.2.10. Others: Sales Forecast 2018-2028
    • 4.2.3. Merck & Co.: SWOT Analysis
  • 4.3. Johnson & Johnson: Overview
    • 4.3.1. Johnson & Johnson: Antibiotics Drugs Portfolio
    • 4.3.2. Johnson & Johnson Antibiotics Drug Sales Forecast 2018-2028
      • 4.3.2.1. Zeftera
      • 4.3.2.2. Zeftera: Sales Forecast 2018-2028
      • 4.3.2.3. Sirturo
      • 4.3.2.4. Sirturo: Sales Forecast 2018-2028
      • 4.3.2.5. Others
      • 4.3.2.6. Others: Sales Forecast 2018-2028
    • 4.3.3. Johnson & Johnson: SWOT Analysis
  • 4.4. Cubist Pharmaceuticals: Overview
    • 4.4.1. Cubist Pharmaceuticals: Antibiotics Drugs Portfolio
    • 4.4.2. Cubist Pharmaceuticals Antibiotics Drug Sales Forecast 2018-2028
      • 4.4.2.1. Cubicin
      • 4.4.2.2. Cubicin: Sales Forecast 2018-2028
      • 4.4.2.3. Sivextro Oral (Tedizolid)
      • 4.4.2.4. Sivextro Oral: Sales Forecast 2018-2028
      • 4.4.2.5. Others
      • 4.4.2.6. Others: Sales Forecast 2018-2028
    • 4.4.3. Cubist Pharmaceuticals.: SWOT Analysis
  • 4.5. Abbott Laboratories: Overview
    • 4.5.1. Abbott Laboratories: Antibiotics Drugs Portfolio
    • 4.5.2. Abbott Laboratories Antibiotics Drug Sales Forecast 2018-2028
      • 4.5.2.1. Baxin
      • 4.5.2.2. Baxin: Sales Forecast 2018-2028
      • 4.5.2.3. Others
      • 4.5.2.4. Others: Sales Forecast 2018-2028
    • 4.5.3. Abbott Laboratories.: SWOT Analysis
  • 4.6. Eli Lilly & Co.: Overview
    • 4.6.1. Eli Lilly & Co.: Antibiotics Drugs Portfolio
    • 4.6.2. Eli Lilly & Co. Antibiotics Drug Sales Forecast 2018-2028
      • 4.6.2.1. Vancocin
      • 4.6.2.2. Vancocin: Sales Forecast 2018-2028
      • 4.6.2.3. Ceclor
      • 4.6.2.4. Ceclor: Sales Forecast 2018-2028
    • 4.6.3. Eli Lilly & Co.: SWOT Analysis
  • 4.7. Melinta Therapeutics, Inc.: Overview
    • 4.7.1. Melinta Therapeutics, Inc.: Antibiotics Drugs Portfolio
    • 4.7.2. Melinta Therapeutics, Inc. Antibiotics Drug Sales Forecast 2018-2028
      • 4.7.2.1. Orbactiv
      • 4.7.2.2. Orbactiv: Sales Forecast 2018-2028
      • 4.7.2.3. Others
      • 4.7.2.4. Others: Sales Forecast 2018-2028
    • 4.7.3. Melinta Therapeutics, Inc: SWOT Analysis

5. Leading Europe Antibiotics Drugs Manufacturers 2018-2028

  • 5.1. Novartis: Overview
    • 5.1.1. Novartis: Antibiotics Drugs Portfolio
    • 5.1.2. Novartis Antibiotics Drug Sales Forecast 2018-2028
      • 5.1.2.1. Vigamox
      • 5.1.2.2. Vigamox: Sales Forecast 2018-2028
      • 5.1.2.3. Ciprodex
      • 5.1.2.4. Ciprodex: Sales Forecast 2018-2028
      • 5.1.2.5. TOBI Podhaler
      • 5.1.2.6. TOBI Podhaler: Sales Forecast 2018-2028
      • 5.1.2.7. Cubicin
      • 5.1.2.8. Cubicin: Sales Forecast 2018-2028
    • 5.1.3. Novartis: SWOT Analysis
  • 5.2. GlaxoSmithKline plc: Overview
    • 5.2.1. GlaxoSmithKline plc: Antibiotics Drugs Portfolio
    • 5.2.2. GlaxoSmithKline plc Antibiotics Drug Sales Forecast 2018-2028
      • 5.2.2.1. Ceftin/Zinnat
      • 5.2.2.2. Ceftin/Zinnat: Sales Forecast 2018-2028
      • 5.2.2.3. Augmentin IR
      • 5.2.2.4. Augmentin IR: Sales Forecast 2018-2028
      • 5.2.2.5. Amoxil (Amoxicillin)
      • 5.2.2.6. Amoxil: Sales Forecast 2018-2028
      • 5.2.2.7. Others
      • 5.2.2.8. Others: Sales Forecast 2018-2028
    • 5.2.3. GlaxoSmithKline plc: SWOT Analysis
  • 5.3. Bayer AG: Overview
    • 5.3.1. Bayer AG: Antibiotics Drugs Portfolio
    • 5.3.2. Bayer AG Antibiotics Drug Sales Forecast 2018-2028
      • 5.3.2.1. Avelox
      • 5.3.2.2. Avelox: Sales Forecast 2018-2028
      • 5.3.2.3. Cipro/Cirpobay
      • 5.3.2.4. Cipro/Cirpobay: Sales Forecast 2018-2028
    • 5.3.3. Bayer AG: SWOT Analysis
  • 5.4. Allergan plc: Overview
    • 5.4.1. Allergan plc: Antibiotics Drugs Portfolio
    • 5.4.2. Allergan plc Antibiotics Drug Sales Forecast 2018-2028
      • 5.4.2.1. Zinforo/Teflaro
      • 5.4.2.2. Zinforo/Teflaro: Sales Forecast 2018-2028
      • 5.4.2.3. Dalbavancin
      • 5.4.2.4. Dalbavancin: Sales Forecast 2018-2028
      • 5.4.2.5. Others
      • 5.4.2.6. Others: Sales Forecast 2018-2028
    • 5.4.3. Allergan plc: SWOT Analysis
  • 5.5. F. Hoffmann-La Roche AG: Overview
    • 5.5.1. F. Hoffmann-La Roche AG: Antibiotics Drugs Portfolio
    • 5.5.2. F. Hoffmann-La Roche AG Antibiotics Drug Sales Forecast 2018-2028
      • 5.5.2.1. Rocephin
      • 5.5.2.2. Rocephin: Sales Forecast 2018-2028
    • 5.5.3. F. Hoffmann-La Roche AG: SWOT Analysis
  • 5.6. Sanofi: Overview
    • 5.6.1. Sanofi: Antibiotics Drugs Portfolio
    • 5.6.2. Sanofi Antibiotics Drug Sales Forecast 2018-2028
      • 5.6.2.1. Targocid
      • 5.6.2.2. Targocid: Sales Forecast 2018-2028
      • 5.6.2.3. Others
      • 5.6.2.4. Others: Sales Forecast 2018-2028
    • 5.6.3. Sanofi: SWOT Analysis
  • 5.7. STADA Arzneimittel: Overview
    • 5.7.1. STADA Arzneimittel: Antibiotics Drugs Portfolio
    • 5.7.2. STADA Arzneimittel Antibiotics Drug Sales Forecast 2018-2028
      • 5.7.2.1. Amoxicillin
      • 5.7.2.2. Amoxicillin: Sales Forecast 2018-2028
      • 5.7.2.3. Diclofenac Sodium
      • 5.7.2.4. Diclofenac Sodium: Sales Forecast 2018-2028
    • 5.7.3. STADA Arzneimittel: SWOT Analysis

6. Leading Japan Antibiotics Drugs Manufacturers 2018-2028

  • 6.1. Shionogi & Co., Ltd.: Overview
    • 6.2.1. Shionogi & Co., Ltd.: Antibiotics Drugs Portfolio
    • 6.1.2. Shionogi & Co., Ltd. Antibiotics Drug Sales Forecast 2018-2028
      • 6.1.2.1. Flomox/Flumarin
      • 6.1.2.2. Flomox/Flumarin: Sales Forecast 2018-2028
      • 6.1.2.3. Others
      • 6.1.2.4. Others: Sales Forecast 2018-2028
    • 6.1.3. Shionogi & Co., Ltd.: SWOT Analysis
  • 6.2. Taisho Pharmaceutical Holdings: Overview
    • 6.2.1. Taisho Pharmaceutical Holdings: Antibiotics Drugs Portfolio
    • 6.2.2. Taisho Pharmaceutical Holdings Antibiotics Drug Sales Forecast 2018-2028
      • 6.2.2.1. Geninax
      • 6.2.2.2. Geninax: Sales Forecast 2018-2028
      • 6.2.2.3. Biaxin/Clarith
      • 6.2.2.4. Biaxin/Clarith: Sales Forecast 2018-2028
      • 6.2.2.5. Zosyn/Tazocin
      • 6.2.2.6. Zosyn/Tazocin: Sales Forecast 2018-2028
      • 6.2.2.7. Other
      • 6.2.2.8. Other: Sales Forecast 2018-2028
    • 6.2.3. Taisho Pharmaceutical Holdings: SWOT Analysis
  • 6.3. Daiichi Sankyo: Overview
    • 6.3.1. Daiichi Sankyo: Antibiotics Drugs Portfolio
    • 6.3.2. Daiichi Sankyo Antibiotics Drug Sales Forecast 2018-2028
      • 6.3.2.1. Cravit
      • 6.3.2.2. Cravit: Sales Forecast 2018-2028
      • 6.3.2.3. Levaquin
      • 6.3.2.4. Levaquin: Sales Forecast 2018-2028
      • 6.3.2.5. Others
      • 6.3.2.6. Others: Sales Forecast 2018-2028
    • 6.3.3. Taisho Pharmaceutical Holdings: SWOT Analysis
  • 6.4. Meiji Holdings Company, Ltd.: Overview
    • 6.4.1. Meiji Holdings Company, Ltd.: Antibiotics Drugs Portfolio
    • 6.4.2. Meiji Holdings Company, Ltd. Antibiotics Drug Sales Forecast 2018-2028
      • 6.4.2.1. Meiact/Spectracef
      • 6.4.2.2. Meiact/Spectracef: Sales Forecast 2018-2028
      • 6.4.2.3. Others
      • 6.4.2.4. Others: Sales Forecast 2018-2028
    • 6.4.3. Meiji Holdings Company, Ltd
  • 6.5. Astellas Pharma: Overview
    • 6.5.1. Astellas Pharma: Antibiotics Drugs Portfolio
    • 6.5.2. Astellas Pharma Antibiotics Drug Sales Forecast 2018-2028
      • 6.5.2.1. Dificid
      • 6.5.2.2. Dificid: Sales Forecast 2018-2028
      • 6.5.2.3. Others
      • 6.5.2.4. Others: Sales Forecast 2018-2028
    • 6.5.3. Astellas Pharma

7. Leading Others Antibiotics Drugs Manufacturers 2018-2028

  • 7.1. Sun Pharmaceutical Industries: Overview
    • 7.1.1. Sun Pharmaceutical Industries: Antibiotics Drugs Portfolio
    • 7.1.2. Sun Pharmaceutical Industries Antibiotics Drug Sales Forecast 2018-2028
      • 7.1.2.1. Ciprofloxacin Hydrochloride
      • 7.1.2.2. Ciprofloxacin Hydrochloride: Sales Forecast 2018-2028
      • 7.1.2.3. Others
      • 7.1.2.4. Others: Sales Forecast 2018-2028
    • 7.1.3. Sun Pharmaceutical Industries: SWOT Analysis
  • 7.2. Cipla: Overview
    • 7.2.1. Cipla: Antibiotics Drugs Portfolio
    • 7.2.2. Cipla Antibiotics Drug Sales Forecast 2018-2028
      • 7.2.2.1. Amoxicillin
      • 7.2.2.2. Amoxicillin: Sales Forecast 2018-2028
      • 7.2.2.3. Others
      • 7.2.2.4. Others: Sales Forecast 2018-2028
    • 7.2.3. Cipla
  • 7.3. Lupin Limited: Overview
    • 7.3.1. Lupin: Antibiotics Drugs Portfolio
    • 7.3.2. Lupin Antibiotics Drug Sales Forecast 2018-2028
      • 7.3.2.1. Cefixime
      • 7.3.2.2. Cefixime: Sales Forecast 2018-2028
      • 7.3.2.3. Cephalexin
      • 7.3.2.4. Cephalexin: Sales Forecast 2018-2028
      • 7.3.2.5. Others
      • 7.3.2.6. Others: Sales Forecast 2018-2028
    • 7.3.3. Lupin: SWOT Analysis
  • 7.4. Shanghai Pharmaceuticals Holding: Overview
    • 7.4.1. Shanghai Pharmaceuticals Holding: Antibiotics Drugs Portfolio
    • 7.4.2. Shanghai Pharmaceuticals Holding Antibiotics Drug Sales Forecast 2018-2028
      • 7.4.2.1. Cefotaxime Sodium
      • 7.4.2.2. Cefotaxime Sodium: Sales Forecast 2018-2028
      • 7.4.2.3. Cefotiam Hydrochloride
      • 7.4.2.4. Cefotiam Hydrochloride: Sales Forecast 2018-2028
      • 7.4.2.5. Ceftriaxone Sodium
      • 7.4.2.6. Ceftriaxone Sodium: Sales Forecast 2018-2028
    • 7.4.3. Shanghai Pharmaceuticals Holding: SWOT Analysis
  • 7.5. Dr. Reddy's Laboratories: Overview
    • 7.5.1. Dr. Reddy's Laboratories: Antibiotics Drugs Portfolio
      • 7.5.2.1. Amoxil
      • 7.5.2.2. Amoxil: Sales Forecast 2018-2028
      • 7.5.2.3. Ciprofloxacin Hydrochloride
      • 7.5.2.4. Ciprofloxacin Hydrochloride: Sales Forecast 2018-2028
    • 7.5.3. Dr. Reddy's Laboratories: SWOT Analysis
  • 7.6. TaiGen Biotechnology: Overview
    • 7.6.1. TaiGen Biotechnology: Antibiotics Drugs Portfolio
    • 7.6.2. TaiGen Biotechnology Antibiotics Drug Sales Forecast 2018-2028
      • 7.6.2.1. Taigexyn
      • 7.6.2.2. Taigexyn: Sales Forecast 2018-2028
    • 7.4.3. TaiGen Biotechnology

8. Conclusions

  • 8.1. The World Antibiotics Drugs Market in 2016 and 2017
    • 8.1.1. Current Leading Antibiotics Drugs Segments
    • 8.1.2. Leading Antibiotics Drugs Manufacturer Markets
  • 8.2. World Antibiotics drugs Market Forecast 2018-2028
  • 8.3. The Future of the Antibiotics drugs Market?

Appendix

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 3.1: Global Antibiotics Drugs Market by Product Type: Revenue ($m) and Market Share (%), 2017
  • Table 3.2: Global Antibiotics Drugs Market Forecast, By Automation Type: Revenues ($m), AGR (%), CAGR (%), 2016-2028
  • Table 3.3: Top 10 Antibiotics Drugs Manufacturer: Revenue ($m), Market Share (%), 2017
  • Table 3.4: Top 25 Antibiotics Drugs Manufacturer Revenue ($m), 2017
  • Table 3.5: Global Antibiotics Drugs Market Forecast, By Manufacturer: Revenues ($m), AGR (%), CAGR (%), 2016-2028
  • Table 3.6: Global Antibiotics Drugs Market Forecast, By Product Type: Revenues ($m), AGR (%), CAGR (%), 2016-2028
  • Table 3.7: Cephalosporins Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
  • Table 3.8: Penicillins Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
  • Table 3.9: Fluoroquinolones Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
  • Table 3.10: Macrolides Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
  • Table 3.11: Carbapenems Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
  • Table 3.12: Others Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
  • Table 4.1: Pfizer, Inc.: Overview, 2018
  • Table 4.2: Pfizer: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 4.3: Pfizer Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.4: Pfizer: Sulperazon Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.5: Pfizer: Unasyn Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.6: Pfizer: Zithromax Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.7: Pfizer: Dalacin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.8: Pfizer: Merrem/Meropen Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.9: Pfizer: Zyvox Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.10: Pfizer: Tygacil Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.11: Pfizer: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.12: Pfizer: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 4.13: Merck & Co.: Overview, 2018
  • Table 4.14: Merck & Co.: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 4.15: Merck & Co. Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.16: Merck & Co.: Cubicin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.17: Merck & Co.: Invanz Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.18: Merck & Co.: Avelox Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.19: Merck & Co.: Primaxin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.20: Merck & Co.: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.21: Merck & Co.: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 4.22: Johnson & Johnson: Overview, 2018
  • Table 4.23: Johnson & Johnson: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 4.24: Johnson & Johnson Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.25: Johnson & Johnson: Zeftera Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.26: Johnson & Johnson: Sirturo Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.27: Johnson & Johnson: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.28: Johnson & Johnson: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 4.29: Cubist Pharmaceuticals: Overview, 2018
  • Table 4.30: Cubist Pharmaceuticals: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 4.31: Cubist Pharmaceuticals Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.32: Cubist Pharmaceuticals: Cubicin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.33: Cubist Pharmaceuticals: Sivextro Oral Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.34: Cubist Pharmaceuticals: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.35: Cubist Pharmaceuticals: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 4.36: Abbott Laboratories: Overview, 2018
  • Table 4.37: Abbott Laboratories: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 4.38: Abbott Laboratories Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.39: Abbott Laboratories: Baxin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.40: Abbott Laboratories: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.41: Abbott Laboratories: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 4.42: Eli Lilly & Co.: Overview, 2018
  • Table 4.43: Eli Lilly & Co.: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 4.44: Eli Lilly & Co. Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.45: Eli Lilly & Co.: Vancocin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.46: Eli Lilly & Co.: Ceclor Revenue ($m), AGR (%) and CAGR (%), 2016-2021
  • Table 4.47: Eli Lilly & Co.: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 4.48: Melinta Therapeutics, Inc.: Overview, 2018
  • Table 4.49: Melinta Therapeutics, Inc.: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 4.50: Melinta Therapeutics, Inc. Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.51: Melinta Therapeutics, Inc: Orbactiv Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.52: Melinta Therapeutics, Inc: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.53: Melinta Therapeutics, Inc.: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 5.1: Novartis: Overview, 2018
  • Table 5.2: Novartis: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 5.3: Novartis Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.4: Novartis: Vigamox Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.5: Novartis: Ciprodex Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.6: Novartis: TOBI Podhaler Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.7: Novartis: Cubicin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.8: Novartis: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 5.9: GlaxoSmithKline plc: Overview, 2018
  • Table 5.10: GlaxoSmithKline plc: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 5.11: GlaxoSmithKline plc Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.12: GlaxoSmithKline plc: Ceftin/Zinnat Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.13: GlaxoSmithKline plc: Augmentin IR Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.14: GlaxoSmithKline plc: Amoxil Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.15: GlaxoSmithKline plc: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.16: GlaxoSmithKline plc: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 5.17: Bayer AG: Overview, 2018
  • Table 5.18: Bayer AG: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 5.19: Bayer AG Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.20: Bayer AG: Avelox Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.21: Bayer AG: Cipro/Cirpobay Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.22: Bayer AG: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 5.23: Allergan plc: Overview, 2018
  • Table 5.24: Allergan plc: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 5.25: Allergan plc Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.26: Allergan plc: Zinforo/Teflaro Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.27: Allergan plc: Dalbavancin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.28: Allergan plc: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.29: Allergan plc: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 5.30: F. Hoffmann-La Roche AG: Overview, 2018
  • Table 5.31: F. Hoffmann-La Roche AG: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 5.32: F. Hoffmann-La Roche AG Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.33: F. Hoffmann-La Roche AG: Rocephin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.34: F. Hoffmann-La Roche AG: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 5.35: Sanofi: Overview, 2018
  • Table 5.36: Sanofi: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 5.37: Sanofi Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.38: Sanofi: Targocid Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.39: Sanofi: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.40: Sanofi: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 5.41: STADA Arzneimittel: Overview, 2018
  • Table 5.42: STADA Arzneimittel: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 5.43: STADA Arzneimittel Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.44: STADA Arzneimittel: Amoxicillin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.45: STADA Arzneimittel: Diclofenac Sodium Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.46: STADA Arzneimittel: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 6.1: Shionogi & Co., Ltd.: Overview, 2018
  • Table 6.2: Shionogi & Co., Ltd.: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 6.3: Shionogi & Co., Ltd. Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.4: Shionogi & Co., Ltd.: Flomox/Flumarin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.5: Shionogi & Co., Ltd.: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.6: Shionogi & Co., Ltd.: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 6.7: Taisho Pharmaceutical Holdings: Overview, 2018
  • Table 6.8: Taisho Pharmaceutical Holdings: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 6.9: Taisho Pharmaceutical Holdings Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.10: Taisho Pharmaceutical Holdings: Geninax Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.11: Taisho Pharmaceutical Holdings: Biaxin/Clarith Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.12: Taisho Pharmaceutical Holdings: Zosyn/Tazocin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.13: Taisho Pharmaceutical Holdings: Other Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.14: Taisho Pharmaceutical Holdings: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 6.15: Daiichi Sankyo: Overview, 2018
  • Table 6.16: Daiichi Sankyo: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 6.17: Daiichi Sankyo Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.18: Daiichi Sankyo: Cravit Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.19: Daiichi Sankyo: Levaquin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.20: Daiichi Sankyo: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.21: Taisho Pharmaceutical Holdings: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 6.22: Meiji Holdings Company, Ltd.: Overview, 2018
  • Table 6.23: Meiji Holdings Company, Ltd.: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 6.24: Meiji Holdings Company, Ltd. Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.25: Meiji Holdings Company, Ltd.: Meiact/Spectracef Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.26: Meiji Holdings Company, Ltd.: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.27: Meiji Holdings Company, Ltd: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 6.28: Astellas Pharma: Overview, 2018
  • Table 6.29: Astellas Pharma: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 6.30: Astellas Pharma Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.31: Astellas Pharma: Dificid Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.32: Astellas Pharma: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.33: Astellas Pharma: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 7.1: Sun Pharmaceutical Industries: Overview, 2018
  • Table 7.2: Sun Pharmaceutical Industries: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 7.3: Sun Pharmaceutical Industries Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.4: Sun Pharmaceutical Industries: Ciprofloxacin Hydrochloride Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.5: Sun Pharmaceutical Industries: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.6: Sun Pharmaceutical Industries: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 7.7: Cipla: Overview, 2018
  • Table 7.8: Cipla: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 7.9: Cipla Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.10: Cipla: Amoxicillin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.11: Cipla: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.12: Cipla: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 7.13: Lupin: Overview, 2018
  • Table 7.14: Lupin: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 7.15: Lupin Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.16: Lupin: Cefixime Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.17: Lupin: Cephalexin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.18: Lupin: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.19: Lupin: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 7.20: Shanghai Pharmaceuticals Holding: Overview, 2018
  • Table 7.21: Shanghai Pharmaceuticals Holding: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 7.22: Shanghai Pharmaceuticals Holding Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.23: Shanghai Pharmaceuticals Holding: Cefotaxime Sodium Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.24: Shanghai Pharmaceuticals Holding: Cefotiam Hydrochloride Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.25: Shanghai Pharmaceuticals Holding: Ceftriaxone Sodium Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.26: Shanghai Pharmaceuticals Holding: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 7.27: Dr. Reddy's Laboratories: Overview, 2018
  • Table 7.28: Dr. Reddy's Laboratories: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 7.29: Dr. Reddy's Laboratories Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.30: Dr. Reddy's Laboratories: Amoxil Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.31: Dr. Reddy's Laboratories: Ciprofloxacin Hydrochloride Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.32: Dr. Reddy's Laboratories: Antibiotics Drugs Market SWOT Analysis, 2018-2028
  • Table 7.33: TaiGen Biotechnology: Overview, 2018
  • Table 7.34: TaiGen Biotechnology: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 7.35: TaiGen Biotechnology Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.36: TaiGen Biotechnology: Taigexyn Revenue ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.37: TaiGen Biotechnology: Antibiotics Drugs Market SWOT Analysis, 2018-2028

List of Figure

  • Figure 1.1: Global Antibiotics Drugs Manufacturer Market Segmentation Overview
  • Figure 3.1: Global Antibiotics Drugs Market by Product Type: Market Share (%), 2017
  • Figure 3.2: Global Antibiotics Drugs Market by Product Type: Market Share (%), 2017
  • Figure 3.3: Global Antibiotics Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2028
  • Figure 3.4: Top 10 Antibiotics Drugs Manufacturer: Revenue ($m), 2017
  • Figure 3.5: Top 10 Antibiotics Drugs Manufacturer: Market Share (%), 2017
  • Figure 3.6: Global Antibiotics Drugs Market by Automation Type: Market Share (%), 2017
  • Figure 3.7: Global Antibiotics Drugs Market by Automation Type: Market Share (%), 2022
  • Figure 3.8: Global Antibiotics Drugs Market by Automation Type: Market Share (%), 2028
  • Figure 3.9: Global Cephalosporins Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2028
  • Figure 3.10: Global Penicillins Market Forecast: Revenue ($m), AGR (%), 2016-2028
  • Figure 3.11: Global Fluoroquinolones Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2028
  • Figure 3.12: Global Macrolides Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2028
  • Figure 3.13: Global Carbapenems Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2028
  • Figure 3.14: Global Others Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2028
  • Figure 4.1: Pfizer Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 4.2: Pfizer: Sulperazon: Revenue ($m), AGR (%), 2016-2028
  • Figure 4.3: Pfizer: Unasyn Revenue ($m), AGR (%), 2016-2028
  • Figure 4.4: Pfizer: Zithromax Revenue ($m), AGR (%), 2016-2028
  • Figure 4.5: Pfizer: Dalacin Revenue ($m), AGR (%), 2016-2028
  • Figure 4.6: Pfizer: Merrem/Meropen Revenue ($m), AGR (%), 2016-2028
  • Figure 4.7: Pfizer: Zyvox Revenue ($m), AGR (%), 2016-2028
  • Figure 4.8: Pfizer: Tygacil Revenue ($m), AGR (%), 2016-2028
  • Figure 4.9: Others: Tygacil Revenue ($m), AGR (%), 2016-2028
  • Figure 4.10: Merck & Co. Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 4.11: Merck & Co.: Cubicin: Revenue ($m), AGR (%), 2016-2028
  • Figure 4.12: Merck & Co.: Invanz Revenue ($m), AGR (%), 2016-2028
  • Figure 4.13: Merck & Co.: Avelox Revenue ($m), AGR (%), 2016-2028
  • Figure 4.14: Merck & Co.: Primaxin Revenue ($m), AGR (%), 2016-2028
  • Figure 4.15: Merck & Co.: Others Revenue ($m), AGR (%), 2016-2028
  • Figure 4.16: Johnson & Johnson Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 4.17: Johnson & Johnson: Zeftera: Revenue ($m), AGR (%), 2016-2028
  • Figure 4.18: Johnson & Johnson: Sirturo Revenue ($m), AGR (%), 2016-2028
  • Figure 4.19: Johnson & Johnson: Others Revenue ($m), AGR (%), 2016-2028
  • Figure 4.20: Cubist Pharmaceuticals Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 4.21: Cubist Pharmaceuticals: Cubicin: Revenue ($m), AGR (%), 2016-2028
  • Figure 4.22: Cubist Pharmaceuticals: Sivextro Oral Revenue ($m), AGR (%), 2016-2028
  • Figure 4.23: Cubist Pharmaceuticals: Others Revenue ($m), AGR (%), 2016-2028
  • Figure 4.24: Abbott Laboratories Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 4.25: Abbott Laboratories: Baxin Revenue ($m), AGR (%), 2016-2028
  • Figure 4.26: Abbott Laboratories: Tedizolid Revenue ($m), AGR (%), 2016-2028
  • Figure 4.27: Eli Lilly & Co. Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 4.28: Eli Lilly & Co.: Vancocin Revenue ($m), AGR (%), 2016-2028
  • Figure 4.29: Eli Lilly & Co.: Ceclor Revenue ($m), AGR (%), 2016-2021
  • Figure 4.30: Melinta Therapeutics, Inc.Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 4.31: Melinta Therapeutics, Inc.: Orbactiv Revenue ($m), AGR (%), 2016-2028
  • Figure 4.32: Melinta Therapeutics, Inc.: Others Revenue ($m), AGR (%), 2016-2028
  • Figure 5.1: Novartis Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 5.2: Novartis: Vigamox Revenue ($m), AGR (%), 2016-2028
  • Figure 5.3: Novartis: Ciprodex Revenue ($m), AGR (%), 2016-2028
  • Figure 5.4: Novartis: TOBI Podhaler Revenue ($m), AGR (%), 2016-2028
  • Figure 5.5: Novartis: Cubicin Revenue ($m), AGR (%), 2016-2028
  • Figure 5.6: GlaxoSmithKline plc Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 5.7: GlaxoSmithKline plc: Ceftin/Zinnat: Revenue ($m), AGR (%), 2016-2028
  • Figure 5.8: GlaxoSmithKline plc: Augmentin IR Revenue ($m), AGR (%), 2016-2028
  • Figure 5.9: GlaxoSmithKline plc: Amoxil Revenue ($m), AGR (%), 2016-2028
  • Figure 5.10: GlaxoSmithKline plc: Others Revenue ($m), AGR (%), 2016-2028
  • Figure 5.11: Bayer AG Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 5.12: Bayer AG: Avelox Revenue ($m), AGR (%), 2016-2028
  • Figure 5.13: Bayer AG: Cipro/Cirpobay Revenue ($m), AGR (%), 2016-2028
  • Figure 5.14: Allergan plc Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 5.15: Allergan plc: Zinforo/Teflaro Revenue ($m), AGR (%), 2016-2028
  • Figure 5.16: Allergan plc: Dalbavancin Revenue ($m), AGR (%), 2016-2028
  • Figure 5.17: Allergan plc: Others Revenue ($m), AGR (%), 2016-2028
  • Figure 5.18: F. Hoffmann-La Roche AG Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 5.19: F. Hoffmann-La Roche AG: Rocephin Revenue ($m), AGR (%), 2016-2028
  • Figure 5.20: Sanofi Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 5.21: Sanofi: Targocid Revenue ($m), AGR (%), 2016-2028
  • Figure 5.22: Sanofi: Others Revenue ($m), AGR (%), 2016-2028
  • Figure 5.23: STADA ArzneimittelAntibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 5.24: STADA Arzneimittel: Amoxicillin Revenue ($m), AGR (%), 2016-2028
  • Figure 5.25: STADA Arzneimittel: Diclofenac Sodium Revenue ($m), AGR (%), 2016-2028
  • Figure 6.1: Shionogi & Co., Ltd. Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 6.2: Shionogi & Co., Ltd.: Flomox/Flumarin Revenue ($m), AGR (%), 2016-2028
  • Figure 6.3: Shionogi & Co., Ltd.: Others Revenue ($m), AGR (%), 2016-2028
  • Figure 6.4: Taisho Pharmaceutical Holdings Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 6.5: Taisho Pharmaceutical Holdings: Geninax Revenue ($m), AGR (%), 2016-2028
  • Figure 6.6: Taisho Pharmaceutical Holdings: Biaxin/Clarith Revenue ($m), AGR (%), 2016-2028
  • Figure 6.7: Taisho Pharmaceutical Holdings: Zosyn/Tazocin Revenue ($m), AGR (%), 2016-2028
  • Figure 6.8: Taisho Pharmaceutical Holdings: Other Revenue ($m), AGR (%), 2016-2028
  • Figure 6.9: Daiichi Sankyo Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 6.10: Daiichi Sankyo: Cravit Revenue ($m), AGR (%), 2016-2028
  • Figure 6.11: Daiichi Sankyo: Levaquin Revenue ($m), AGR (%), 2016-2028
  • Figure 6.12: Daiichi Sankyo: Others Revenue ($m), AGR (%), 2016-2028
  • Figure 6.13: Meiji Holdings Company, Ltd. Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 6.14: Meiji Holdings Company, Ltd.: Meiact/Spectracef Revenue ($m), AGR (%), 2016-2028
  • Figure 6.15: Meiji Holdings Company, Ltd.: Others Revenue ($m), AGR (%), 2016-2028
  • Figure 6.16: Astellas Pharma Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 6.17: Astellas Pharma: Dificid Revenue ($m), AGR (%), 2016-2028
  • Figure 6.18: Astellas Pharma: Tedizolid Revenue ($m), AGR (%), 2016-2028
  • Figure 7.1: Sun Pharmaceutical Industries Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 7.2: Sun Pharmaceutical Industries: Ciprofloxacin Hydrochloride Revenue ($m), AGR (%), 2016-2028
  • Figure 7.3: Sun Pharmaceutical Industries: Others Revenue ($m), AGR (%), 2016-2028
  • Figure 7.4: Cipla Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 7.5: Cipla: Amoxicillin Revenue ($m), AGR (%), 2016-2028
  • Figure 7.6: Cipla: Others Revenue ($m), AGR (%), 2016-2028
  • Figure 7.7: Lupin Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 7.8: Lupin: Cefixime Revenue ($m), AGR (%), 2016-2028
  • Figure 7.9: Lupin: Cephalexin Revenue ($m), AGR (%), 2016-2028
  • Figure 7.10: Lupin: Others Revenue ($m), AGR (%), 2016-2028
  • Figure 7.11: Shanghai Pharmaceuticals Holding Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 7.12: Shanghai Pharmaceuticals Holding: Cefotaxime Sodium Revenue ($m), AGR (%), 2016-2028
  • Figure 7.13: Shanghai Pharmaceuticals Holding: Tedizolid Revenue ($m), AGR (%), 2016-2028
  • Figure 7.14: Shanghai Pharmaceuticals Holding: Ceftriaxone Sodium Revenue ($m), AGR (%), 2016-2028
  • Figure 7.15: Dr. Reddy's Laboratories Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 7.16: Dr. Reddy's Laboratories: Amoxil Revenue ($m), AGR (%), 2016-2028
  • Figure 7.17: Dr. Reddy's Laboratories: Ciprofloxacin Hydrochloride Revenue ($m), AGR (%), 2016-2028
  • Figure 7.18: TaiGen Biotechnology Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028
  • Figure 7.19: TaiGen Biotechnology: Taigexyn Revenue ($m), AGR (%), 2016-2028
  • Figure 8.1: Global Antibiotics drugs Market by Product Type: Market Share (%), 2016
  • Figure 8.2: Top Antibiotics drugs Manufacturer Share (%), 2016

COMPANIES LISTED

  • Abbott Labs
  • Actavis plc
  • Akorn, Inc
  • Allergan plc
  • AMAG Pharmaceuticals, Inc.
  • Astellas Pharma
  • AstraZeneca plc
  • Basilea Pharmaceutica
  • Bayer AG
  • Bristol-MyersSquibb
  • Cempra Pharmaceuticals
  • Chattem, Inc.
  • Ciba-Geigy
  • Cipla
  • Cubist Pharmaceuticals
  • Daiichi Sankyo C
  • Dr. Reddy's Laboratories
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche AG
  • Forest Laboratories, Inc.
  • Genzyme Corporation
  • GSK
  • Hospira Inc.
  • Johnson & Johnson
  • LG Life Sciences
  • Lupin
  • Meiji Holdings
  • Melinta Therapeutics, Inc
  • Merck & Co.
  • Merck Sharp & Dohme
  • Nestle
  • Novartis
  • Onco Therapy Science, Inc.
  • Ophthotech
  • Pfizer Inc.
  • Pharmacia
  • Purdue Pharma L.P.
  • Sandoz
  • Sanofi
  • Shanghai Pharmaceuticals Holding
  • Shionogi & Co., Ltd.
  • Shionogi, Inc.
  • Shire plc
  • STADA Arzneimittel
  • Sun Pharmaceutical Industries
  • TaiGen Biotechnology
  • Taisho Pharmaceutical Holdings
  • Upjohn
  • Warner-Lambert
  • Wyeth Pharmaceuticals
  • Zentiva
  • Zoetis

Other Organisations Mentioned in This Report:

  • European Centre for Disease Prevention and Control (ECDC)
  • European Commission
  • Food and Drug Administration
  • Government of Sweden
  • Infectious Disease Society of America
  • Joint United Nations Programme on HIV/AIDS (UNAIDS)
  • National Action Plan for Combating Antibiotic-Resistant Bacteria
  • National Center for Biotechnology Information
  • National Institute of Allergy and Infectious Diseases
  • Southeast Asian World Health Organization
  • U.S. Centers for Disease Control and Prevention
  • United States Food and Drug Administration (USFDA)
  • US Bureau of Labor Statistics
  • World Health Assembly
  • World Health Organization